About: Rituximab Plus Intensive Chemotherapy Does Not Adversely Affect the Peripheral Stem Cell Mobilization and Engraftment after Hig-Dose Therapy and Autologous Stem Cell Transplantation is Patients with Diffuse Large B-Cell Lymphoma in First Complete or Partial Remission

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Rituximab Plus Intensive Chemotherapy Does Not Adversely Affect the Peripheral Stem Cell Mobilization and Engraftment after Hig-Dose Therapy and Autologous Stem Cell Transplantation is Patients with Diffuse Large B-Cell Lymphoma in First Complete or Partial Remission Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Aims and Methods: The goal was to investigate the effect of prior combined rituximab (R) and intensive chemotherapy on peripheral blood stem cell mobilization and their engraftment after stem cell transplantation (ASCT) in 69 patients with poor-risk, diffuse large B-cell lymphoma (DLBCL). Results: A statistically comparable median number of CD34+ stem cells was collected in both groups (13.80x106/ kg in the non-R group and 7.81x106/kg in the R group; p = 0.110). A trend toward greater number of CFU-GM was found in the non-R group (98.1x104/kg) compared to the R group (76.6x104/kg; p = 0.068). The non-R patients had a much higher median number of BFU-E (90.9x104/kg) than the R patients (31.3x104/kg; p = 0.001). Conclusions: Hematopoietic engraftment was rapid for both groups and no different between them. The 3-year event-free survival was 90.4 % in the R group and 67.2 % in the non-R group (p = 0.04), but there was no significant difference in the 3-year overall survival Aims and Methods: The goal was to investigate the effect of prior combined rituximab (R) and intensive chemotherapy on peripheral blood stem cell mobilization and their engraftment after stem cell transplantation (ASCT) in 69 patients with poor-risk, diffuse large B-cell lymphoma (DLBCL). Results: A statistically comparable median number of CD34+ stem cells was collected in both groups (13.80x106/ kg in the non-R group and 7.81x106/kg in the R group; p = 0.110). A trend toward greater number of CFU-GM was found in the non-R group (98.1x104/kg) compared to the R group (76.6x104/kg; p = 0.068). The non-R patients had a much higher median number of BFU-E (90.9x104/kg) than the R patients (31.3x104/kg; p = 0.001). Conclusions: Hematopoietic engraftment was rapid for both groups and no different between them. The 3-year event-free survival was 90.4 % in the R group and 67.2 % in the non-R group (p = 0.04), but there was no significant difference in the 3-year overall survival (en)
Title	Rituximab Plus Intensive Chemotherapy Does Not Adversely Affect the Peripheral Stem Cell Mobilization and Engraftment after Hig-Dose Therapy and Autologous Stem Cell Transplantation is Patients with Diffuse Large B-Cell Lymphoma in First Complete or Partial Remission Rituximab Plus Intensive Chemotherapy Does Not Adversely Affect the Peripheral Stem Cell Mobilization and Engraftment after Hig-Dose Therapy and Autologous Stem Cell Transplantation is Patients with Diffuse Large B-Cell Lymphoma in First Complete or Partial Remission (en)
skos:prefLabel	Rituximab Plus Intensive Chemotherapy Does Not Adversely Affect the Peripheral Stem Cell Mobilization and Engraftment after Hig-Dose Therapy and Autologous Stem Cell Transplantation is Patients with Diffuse Large B-Cell Lymphoma in First Complete or Partial Remission Rituximab Plus Intensive Chemotherapy Does Not Adversely Affect the Peripheral Stem Cell Mobilization and Engraftment after Hig-Dose Therapy and Autologous Stem Cell Transplantation is Patients with Diffuse Large B-Cell Lymphoma in First Complete or Partial Remission (en)
skos:notation	RIV/61989592:15110/09:33116051!RIV12-MSM-15110___
http://linked.open...avai/riv/aktivita	Z
http://linked.open...avai/riv/aktivity	Z(MSM6198959205)
http://linked.open...iv/cisloPeriodika	3
http://linked.open...vai/riv/dodaniDat	2012
http://linked.open...aciTvurceVysledku	Raida, Luděk Vondráková, Jana Skoumalová, Ivana PAPAJÍK, Tomáš Kubová, Zuzana Faber, Edgar INDRÁK, Karel Procházka, Vít Pikalová, Zuzana
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Univerzita Palackého v Olomouci / Lékařská fakulta
http://linked.open...dnocenehoVysledku	339439
http://linked.open...ai/riv/idVysledku	RIV/61989592:15110/09:33116051
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	stem cell transplantation; rituximab; diffuse large B-cell lymphoma (en)
http://linked.open.../riv/klicoveSlovo	rituximab diffuse large B-cell lymphoma stem cell transplantation
http://linked.open...odStatuVydavatele	CZ - Česká republika
http://linked.open...ontrolniKodProRIV	[1A9E1EAD31BD]
http://linked.open...i/riv/nazevZdroje	Biomedical Papers-Olomouc
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	9 (xsd:int)
http://linked.open...cetTvurcuVysledku	12 (xsd:int)
http://linked.open...UplatneniVysledku	2009
http://linked.open...v/svazekPeriodika	153
http://linked.open...iv/tvurceVysledku	Dušek, L. Faber, Edgar Indrák, Karel Kubová, Zuzana Pikalová, Zuzana Raida, Luděk Skoumalová, Ivana Vondráková, Jana Procházka, Vít Pavlík, T. Papajík, Tomáš Kucerová, Z.
http://linked.open...n/vavai/riv/zamer	Studies of genes and molecular mechanisms involved in regulation of hematopoiesis, their clinical impact and targeted treatment
issn	1213-8118
number of pages	4 (xsd:int)
http://localhost/t...ganizacniJednotka	15110
is http://linked.open...avai/riv/vysledek of	Rituximab Plus Intensive Chemotherapy Does Not Adversely Affect the Peripheral Stem Cell Mobilization and Engraftment after Hig-Dose Therapy and Autologous Stem Cell Transplantation is Patients with Diffuse Large B-Cell Lymphoma in First Complete or Partial Remission Rituximab Plus Intensive Chemotherapy Does Not Adversely Affect the Peripheral Stem Cell Mobilization and Engraftment after Hig-Dose Therapy and Autologous Stem Cell Transplantation is Patients with Diffuse Large B-Cell Lymphoma in First Complete or Partial Remission

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 112 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software